Association of PPIs use with short-term and long-term mortality risk in patients with severe ischemic stroke: a retrospective cohort study based on the MIMIC-Ⅲ database

Published on Jan. 31, 2024Total Views: 380 times Total Downloads: 177 times Download Mobile

Author: QIN Sisi ¹ ZHANG Huitao ¹ PAN Haiyan ¹ ZHU Yaoli ¹  ZENG Li ²

Affiliation: 1. Department of Critical Care Medicine, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China 2. Department of Neurology, the Second Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang 550003, China

Keywords: Proton pump inhibitors Severe ischemic stroke Mortality risk MIMIC-Ⅲ database

DOI: 10.12173/j.issn.1005-0698.202306088

Reference: QIN Sisi, ZHANG Huitao, PAN Haiyan, ZHU Yaoli, ZENG Li.Association of PPIs use with short-term and long-term mortality risk in patients with severe ischemic stroke: a retrospective cohort study based on the MIMIC-Ⅲ database[J].Yaowu Liuxingbingxue Zazhi,2024, 33(1):45-51.DOI: 10.12173/j.issn.1005-0698.202306088.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To investigate the association of proton pump inhibitors (PPIs) use with short-term and long-term mortality risk in patients with severe ischemic stroke.

Methods This retrospective study based on the U.S. Medical Information Mark for Intensive Care Ⅲ (MIMIC-Ⅲ) database, ICU patients aged ≥18 years with the first ICU admission and a diagnosis of ischemic stroke were finally included in the study. All enrolled subjects were divided into PPIs group and non-PPIs group according to whether they had used PPIs (pantoprazole, lansoprazole and omeprazole) during hospitalization. Kaplan-Meier survival analyses and Cox regression models were used to analyze the association between the use of PPIs and the risk of ICU death, 30 d risk of death, 90 d risk of death in patients with severe ischemic stroke.

Results A total of 1 015 patients were included, 402 cases in the PPIs group and 613 in the non-PPIs group. The ICU-mortality, 30 d and 90 d mortality were 15.37%, 13.60% and 20.10%, respectively. Kaplan-Meier survival analyses illustrated that the PPIs group survived better than non-PPIs group in ICU mortality analysis (P=0.002). In Cox regression analysis, after adjustment for potential confounders, the hazard ratio (HR) for ICU mortality in the PPIs group relative to the non-PPIs group was 0.671 9 (95%CI 0.478 8 to 0.942 8, P=0.021), but there was no significant difference between 30 d and 90 d mortality (P>0.05).

Conclusion In patients with severe ischemic stroke, the use of PPIs may be effective in reducing the risk of ICU death, but does not improve 30 d and 90 d risk of death in patients.

Full-text

Please download the PDF version to read the full text: download

References

1.Sarnaik MK, Modi S, Pisipati Y, et al. Proton pump inhibitors: exploring cardiovascular complications and prescription protocol[J]. Cureus, 2021, 13(7): e16744. DOI: 10.7759/cureus.16744.

2.Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study[J]. BMJ, 2019, 365: l1580. DOI: 10.1136/bmj.l1580.

3.Li T, Xie Y, Al-Aly Z. The association of proton pump inhibitors and chronic kidney disease: cause or confounding[J]. Curr Opin Nephrol Hypertens, 2018, 27(3): 182-187. DOI: 10.1097/mnh.0000000000000406.

4.Mendelson SJ, Prabhakaran S. Diagnosis and management of transient ischemic attack and acute ischemic stroke: a review[J]. JAMA, 2021, 325(11): 1088-1098. DOI: 10. 1001/jama.2020.26867.

5.Kawakubo K, Fujishima M. Management of gastrointestinal mucosal damage in patients with cerebrovascular disease[J]. Nihon Rinsho, 2002, 60(8): 1573-1579. https://pubmed.ncbi.nlm.nih.gov/12187753/.

6.Wang YF, Chen YT, Luo JC, et al. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study[J]. Am J Gastroenterol, 2017, 112(7): 1084-1093. DOI: 10.1038/ajg.2017.101.

7.Fang L, Zhong W, Gong X, et al. Association of proton pump inhibitor prophylaxis on clinical outcome in acute ischemic stroke in China: a multicenter retrospective cohort study[J]. J Clin Med, 2022, 11(23): 6881. DOI: 10.3390/jcm11236881.

8.Yang J, Li Y, Liu Q, et al. Brief introduction of medical database and data mining technology in big data era[J]. J Evid Based Med, 2020, 13(1): 57-69. DOI: 10.1111/jebm.12373.

9.Johnson AE, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database[J]. Sci Data, 2016, 3: 160035. DOI: 10.1038/sdata.2016.35.

10.Beltrán Romero LM, Vallejo-Vaz AJ, Muñiz Grijalvo O. Cerebrovascular disease and statins[J]. Front Cardiovasc Med, 2021, 8: 778740. DOI: 10.3389/fcvm.2021.778740.

11.Radak D, Resanovic I, Isenovic ER. Link between oxidative stress and acute brain ischemia[J]. Angiology, 2014, 65(8): 667-676. DOI: 10.1177/0003319713506516.

12.Pluta R, Januszewski S, Czuczwar SJ. The role of gut microbiota in an ischemic stroke[J]. Int J Mol Sci, 2021, 22(2): 915. DOI: 10.3390/ijms22020915.

13.Misra UK, Kalita J, O'Donnell MJ, et al. Gastrointestinal bleeding after acute ischemic stroke[J]. Neurology, 2009, 73(2): 160-161. DOI: 10.1212/WNL.0b013e3181ab9b46.

14.Camara-Lemarroy CR, Ibarra-Yruegas BE, Gongora-Rivera F. Gastrointestinal complications after ischemic stroke[J]. J Neurol Sci, 2014, 346(1-2): 20-25. DOI: 10.1016/j.jns.2014.08.027.

15.Fu J. Factors affecting the occurrence of gastrointestinal bleeding in acute ischemic stroke patients[J]. Medicine (Baltimore), 2019, 98(28): e16312. DOI: 10.1097/md. 0000000000016312.

16.Mo J, Huang L, Peng J, et al. Autonomic disturbances in acute cerebrovascular disease[J]. Neurosci Bull, 2019, 35(1): 133-144. DOI: 10.1007/s12264-018-0299-2.

17.Clarke K, Adler N, Agrawal D, et al. Indications for the use of proton pump inhibitors for stress ulcer prophylaxis and peptic ulcer bleeding in hospitalized patients[J]. Am J Med, 2022, 135(3): 313-317. DOI: 10.1016/j. amjmed.2021.09.010.

18.Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(2): 98-107. DOI: 10.1038/nrgastro. 2014.235.

19.Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients[J]. J Crit Care, 2005, 20(1): 35-45. DOI: 10.1016/j.jcrc.2004.10.003.

20.Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients[J]. N Engl J Med, 2018, 378(26): 2506-2516. DOI: 10.1056/NEJMra1605507.

21.Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine[J]. Circulation, 2013, 128(8): 845-853. DOI: 10.1161/circulationaha.113.003602.

22.Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study[J]. Ann Intern Med, 2010, 153(6): 378-386. DOI: 10.7326/0003-4819-153-6-201009210-00005.

23.Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis[J]. JAMA Neurol, 2016, 73(4): 410-416. DOI: 10.1001/jamaneurol. 2015.4791.

24.Marchina S, Doros G, Modak J, et al. Acid-suppressive medications and risk of pneumonia in acute stroke patients: a systematic review and meta-analysis[J]. J Neurol Sci, 2019, 400: 122-128. DOI: 10.1016/j.jns.2019.02.041.

25.Yepuri G, Sukhovershin R, Nazari-Shafti TZ, et al. Proton pump inhibitors accelerate endothelial senescence[J]. Circ Res, 2016, 118(12): e36-e42. DOI: 10.1161/circresaha. 116.308807.

26.Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice[J]. Circulation, 2012, 126(6): 753-767. DOI: 10.1161/circulationaha.112.093245.

27.Sehested TSG, Gerds TA, Fosbøl EL, et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction[J]. J Intern Med, 2018, 283(3): 268-281. DOI: 10.1111/joim.12698.

28.Taffi R, Nanetti L, Mazzanti L, et al. Plasma levels of nitric oxide and stroke outcome[J]. J Neurol, 2008, 255(1): 94-98. DOI: 10.1007/s00415-007-0700-y.